Research Article
The Expression of Serum lncRNA MIR17HG in Patients with Multiple Myeloma and Its Clinical Significance
Table 2
Clinical baseline data of the subjects.
| | | HC (N = 85) | MM (N = 108) | |
| | Gender (male, %) | 53 (62.35%) | 69 (63.89%) | 0.8261 |
| | Age | 54 (49, 58) | 54 (50, 58) | 0.4297 | | Biochemical indexes | | | | | Scr (mg/dL) | 0.72 ± 0.19 | 1.86 ± 0.41 | <0.001 | | ALB (g/L) | 42.80 ± 4.00 | 33.51 ± 4.08 | <0.001 | | β2-MG (mg/L) | 1.51 ± 0.33 | 5.88 ± 2.37 | <0.001 | | LDH (U/L) | 149.40 ± 28.33 | 265.10 ± 52.06 | <0.001 | | Calcium (mg/dL) | 7.86 (7.35, 8.49) | 12.22 (8.92, 12.66) | <0.001 | | Hb (g/L) | 140.50 ± 19.88 | 88.62 ± 25.30 | <0.001 | | IgG (g/L) | 16.50 ± 5.84 | 8.26 ± 3.27 | <0.001 | | IgA (g/L) | 2.03 ± 0.51 | 8.30 ± 3.24 | <0.001 | | Bone lesions (cases, %) | — | 68 (62.96%) | — | | Renal impairment (cases, %) | — | 38 (35.19%) | — | | DS stage (cases, %) | | | | | I-II | — | 48 (44.44%) | — | | III | — | 60 (55.56%) | — | | ISS stage (cases, %) | | | | | I | — | 15 (13.89%) | — | | II | — | 33 (30.55%) | — | | III | — | 60 (55.56%) | — |
|
|
Notes: Scr, serum creatinine; ALB, albumin; β2-MG, β2-microglobuli; LDH, lactate dehydrogenase; Hb, hemoglobin; IgG, immunoglobulin G; IgA, immunoglobulin A; DS, Durie-Salmon; ISS, international staging system.
|
